Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR

Abstract excerpt

Bladder cancers can be categorized into subtypes according to gene expression patterns. P53-like muscle-invasive bladder cancers are generally resistant to cisplatin-based chemotherapy, but exhibit heterogeneous clinical outcomes with a prognosis intermediate to that of the luminal and basal subtypes. The optimal approach to p53-like tumors remains poorly defined and better means to risk-stratify such tumors and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bladder and Urothelial Cancer Treatments
• Share to Epigenetics and DNA Methylation
• Share to RNA modifications and cancer